Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID03472157

Prospective Multicentric, Open Label, Randomized Study Comparing Bariatric Surgery to Medical Treatment for NASH with Advanced Liver Fibrosis

Led by University Hospital, Lille · Updated on 2026-04-22

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University Hospital, Lille

Lead Sponsor

M

Ministry of Health, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of bariatric surgery compared to standard medical treatment in obese patients with nonalcoholic steatohepatitis (NASH) complicated by advanced liver fibrosis (grades F3 and F4). This study aims to show whether bariatric surgery leads to the disappearance of NASH without worsening fibrosis in patients with a body mass index (BMI) between 30 and 35 kg/m² for F3 fibrosis, and between 30 and 50 kg/m² for F4 fibrosis. The trial is open-label and randomized, designed to compare surgical intervention with lifestyle therapy.

CONDITIONS

Brief Title

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide written informed consent and agree to comply with the study protocol prior to enrollment
  • BMI between 30 and 35 kg/m² for F3 fibrosis or between 30 and 50 kg/m² for F4 fibrosis
  • Fibroscan ≥ 9kPa or FibrometreVM ≤ 0.526 predicting F3 or F4 fibrosis within 1 month before inclusion, or hepatic biopsy confirming F3 or F4 fibrosis
  • Agree to have one liver biopsy during screening and one at the end of treatment for assessment
  • For patients with cirrhosis: platelets > 125,000, PT > 80%, albumin > 35 g/L, MELD score < 9, CPT score < 6, no history of decompensation, no oesophageal varices, no vascular shunt, ASA score ≤ III, and alcohol consumption below defined limits
  • Controlled hypertension with stable medication for at least 2 months prior to screening
  • Females must be non-childbearing or using effective contraception
  • Agree to attend study visits as scheduled
Not Eligible

You will not qualify if you...

  • Previous bariatric surgery except gastric ring removed more than 3 years ago
  • Decompensated cirrhosis or MELD > 7, CPT score > 5, or history of decompensation
  • Hepatocellular carcinoma
  • Platelets < 125,000; PT < 80%; bilirubin < 20 mmol/L; albumin < 35 g/L
  • Other liver diseases such as excessive alcohol use, HBV, HCV, autoimmune hepatitis, hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency
  • Active cancer treatment
  • HIV positive status
  • Recent cardiovascular events within 6 months prior to screening
  • Severe chronic respiratory or cardiac insufficiency
  • Pregnant or breastfeeding women
  • Concurrent enrollment in another clinical trial
  • Drug abuse within the past year
  • Contraindications for bariatric surgery
  • Excluded bariatric surgery types: gastric banding, biliopancreatic diversion, and newer techniques
  • History of cancer except patients in remission for at least 5 years or treated basal/squamous cell carcinoma of the skin or resected cervical carcinoma

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 60 weeks

Participants receive either bariatric surgery with nutritional support and therapeutic education or lifestyle therapy involving diet and increased physical activity.

Regular visits as scheduled during treatment period

Follow-up

Duration - At 60 weeks after randomization

Participants have a liver biopsy and assessments at the end of treatment to evaluate changes in liver condition and metabolic health.

1 visit for end-of-treatment assessment

Trial Site Locations

Total: 1 location

1

Hôpital Claude Huriez, CHRU

Lille, France

Actively Recruiting

Loading map...

Research Team

P

Philippe Mathurin, MD,PhD

G

Guillaume Lassailly, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Clinical Outcomes of Indocyanine Green Tracer in 3D Plus Ult...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here